Enhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified from Escherichia coli O157

American Journal of Hematology

Volumn 66, Issue 2, 2001, Pages 105-115

  Yagi, Hideo ^a   Narita, Nobuhiro ^a   Matsumoto, Masanori ^a   Sakurai, Yoshihiko ^a   Ikari, Hisao ^a   Yoshioka, Akira ^a   Kita, Eiji ^a   Ikeda, Yasuo ^b   Titani, Koiti ^c   Fujimura, Yoshihiro ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Cytokine; Gb3; HUS; Monocyte; SIPA; Stx1

Indexed keywords

VEROTOXIN;

ARTICLE; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

BACTERIAL TOXINS; CHILD; CHILD, PRESCHOOL; CYTOKINES; ESCHERICHIA COLI O157; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; LASERS; LEUKOCYTES; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PLATELET AGGREGATION; RADIOLIGAND ASSAY; SHIGA-LIKE TOXIN I; STRESS, MECHANICAL; TRIHEXOSYLCERAMIDES;

EID: 0035141825     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-8652(200102)66:2<105::AID-AJH1025>3.0.CO;2-1     Document Type: Article

References (24)

1. Hemolytic-uremic syndrome. Current concepts and management
2. The association between idiopathic hemolytic syndrome and infection by verocytotoxin producing Escherichia coli
3. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide
4. Endothelial heterogeneity in Shiga toxin receptors and responses
5. Effects of verotoxin-1 on nonadherent human monocytes: Binding characteristics, protein synthesis and induction of cytokine release
6. Recent advances in understanding the pathogenesis of the hemolytic-uremic syndrome
7. Verotoxin and neurominidase induced platelet-aggregating activity in plasma: Their possible roles in the pathogenesis of the haemolitic-uremic syndrome
8. Platelet aggregating factor in the epidemic form of hemolytic-uremic syndrome in childhood
9. Presence of a platelet aggregation factor in the plasma of patients with thrombotic thrombocytopenic purpura and its inhibition by normal plasma
10. Von Willebrand factor: A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib
11. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib
12. Purification and some properties of Shiga-like toxin from Escherichia coli O157: H7 that is immunologically identical to Shiga toxin
13. Quantitative microtiter cytotoxicity assay for Shigella toxin
14. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress
15. Protein and cell membrane iodinations with sparingly soluble chloramine, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril
16. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro
17. Glycosphingolipid-blotting: An immunological detection procedure after separation by thin-layer chromatography
18. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry
19. Glycolipid receptor for verotoxin
20. Granulocyte colony-stimulating factor and platelet aggregation
21. Platelet activation induced by interleukin-6: Evidence for a mechanism involving arachidonic acid metabolism
22. Interleukin-6 stimulates neutrophil production of platelet-activating factor
23. CV3988 - A specific antagonist of platelet activating factor
24. Abnormalities of factor VIII related protein multimers in the haemolytic-uremic syndrome